This epigenetic and metabolic shift in the tumor microenvironment, as demonstrated in these mouse models, suggests that immune checkpoint blockade coupled with the IFN-γ-TET2 axis can surmount immunosuppression, thereby providing a strategy to counteract the resistance to IDH1 mutation inhibitors. This evidence concerns the gene TET2 and neoplasm.